ALX148

comprised of the N-terminal D1 domain of SIRPalpha, which binds CD47 fused to a modified human IgG1 Fc domain

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 01/01/2018 - "ALX148 binds CD47 from multiple species with high affinity, inhibits wild type SIRPα binding, and enhances phagocytosis of tumor cells by macrophages. " 10/01/2020 - "ALX148, a novel CD47 blocking agent, is in clinical development for the treatment of advanced solid tumors and lymphoma. " 01/01/2018 - "Additionally, ALX148 enhanced the antitumor activity of multiple immunotherapeutic antibodies in syngeneic tumor models. " 01/01/2018 - "Across several murine tumor xenograft models, ALX148 enhanced the antitumor activity of different targeted antitumor antibodies. "
2.	Lymphoma (Lymphomas) 10/01/2020 - "ALX148, a novel CD47 blocking agent, is in clinical development for the treatment of advanced solid tumors and lymphoma. "

1.	Antibodies